The phase 3 KeyVibe-010 trial (NCT05665595) evaluating the combination of adjuvant vibostolimab (MK-7684A) and pembrolizumab (Keytruda) vs pembrolizumab alone in patients with resected high-risk stage IIB, IIC, III, and IV melanoma has been discontinued.
Clinical Trials
Adjuvant Vaccine Combo May Prolong Survival in Melanoma
A multipeptide vaccine combination approach may extend survival in stage IIB to IV melanoma.
FOCUS Trial of HEPZATO KIT Shows Efficacy in Metastatic Uveal Melanoma
A study found that treatment with HEPZATO KIT showed a promising response rate of 36.3% for patients with unresectable metastatic uveal melanoma.
TIL Therapy Promising in Uveal Melanoma, Tool Predicts Responders
A type of therapy that involves “liberating” T cells from a suppressive tumor environment showed promise in the treatment of patients with uveal melanoma.